Cellebrite
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 1 week.
- Recent price momentum is -21.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 2.2% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 43.1x | Better than 12% |
| Forward P/E | 35.1x | Better than 13% |
| Price / Sales | 5.4x | Better than 21% |
| P/E vs own 5-yr range | 82nd pctl | Better than 24% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 20.7% | Better than 83% |
| Net income CAGR (3Y) | -13.4% | Better than 24% |
| Free cash flow CAGR (3Y) | 140.7% | Better than 96% |
Profitability A-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 84.2% | Better than 93% |
| Operating margin | 14.0% | Better than 62% |
| Net margin | 16.4% | Better than 74% |
| Return on equity | 19.0% | Better than 76% |
| Return on invested capital | 13.5% | Better than 79% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -2.5% | Better than 68% |
| 6-month return | -18.3% | Better than 29% |
| 12-month return (ex latest month) | -30.2% | Better than 9% |
| Distance below 52-week high | 44.5% | Better than 24% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.6x | Better than 43% |
| Debt to assets | 2.4% | Better than 87% |
| Interest coverage | 174.4x | Better than 95% |
| Free cash flow / net income | 204.7% | Better than 78% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 39.3% | Better than 59% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 11.32
- Open
- 11.18
- Day range
- 10.72 - 11.41
- Avg price
- 10.91
- Volume
- 2.71M
- Turnover
- 29.57M
- Turnover ratei
- 2.41%
- Volume ratioi
- 0.88
- Amplitudei
- 6.10%
- 52-week rangei
- 9.58 - 19.39
Valuation
- P/Ei
- 34.74
- P/E (TTM)i
- 43.08
- P/Bi
- 4.67
- EPSi
- 0.31
- Book value / shi
- 2.31
- Net profit
- 77.92M
- Net assets
- 579.34M
Share structure
- Market cap
- 2.71B
- Float capi
- 1.21B
- Shares out
- 251.34M
- Float sharesi
- 112.43M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
44.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-14.73M net over the window
Short interest
- Shares short
- 5.64M
- % of floati
- 2.25%
- Days to coveri
- 4.33
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Cellebrite (CLBT)?
Cellebrite last traded at 10.77. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Cellebrite's market cap?
About 2.71B.
What is the P/E ratio of Cellebrite?
The trailing twelve-month P/E is 43.08, above its own 5-year average of 3.23 — toward the top of its historical range (82.14% percentile). See the Valuation tab for the full history.
Does Cellebrite pay a dividend?
Cellebrite does not currently pay a regular dividend.
Is Cellebrite a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 15.00, which implies 39.3% upside from the current price. This is not investment advice.
What is Cellebrite's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Cellebrite a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Cellebrite discussion 0 comments